Skip to main content
Premium Trial:

Request an Annual Quote

Scale Biosciences, Basepair Partner on Single-Cell Sequencing Informatics

NEW YORK – Scale Biosciences said Monday that it is integrating its single-cell sequencing data pipeline into Basepair's cloud-based bioinformatics analysis platform.

San Diego-based startup ScaleBio will deploy its ScaleBio Seq Suite so researchers can upload FASTQ and BCL files through Basepair's graphical user interface for rapid analysis and report generation. The firm said that this will assist customers in the adoption of single-cell protocols with minimal investment in bioinformatics infrastructure.

"Challenges related to analysis and interpretation of sequencing data are still one of the most common bottlenecks that researchers face when adopting new next-generation sequencing applications, especially those that create large amounts of data," ScaleBio CEO Giovanna Prout said in a statement. "Through our relationship with Basepair, we are making it easier for organizations with limited resources to quickly and cost-effectively go from sample to interpretable data."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.